← All Tonix Pharmaceuticals Holding CORP filings

Tonix Pharmaceuticals Holding CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TNXP
Tonix Pharmaceuticals Holding CORP
10-K: Tonix Pharma Launches Fibromyalgia Drug, Faces Going Concern
Tonix Pharmaceuticals launched its first internally developed FDA-approved product, TONMYA for fibromyalgia, in November 2025, amidst ongoing operating losses and a going concern warning.
NASDAQ
TNXP
Tonix Pharmaceuticals Holding CORP
10-K: Tonix Pharmaceuticals Reports Fiscal Year 2024 Results and Provides Business Update
Tonix Pharmaceuticals submitted an NDA for TNX-102 SL for fibromyalgia and is preparing for a potential commercial launch in Q4 2025, while also advancing its pipeline in CNS, immunology, and infectious diseases.
NASDAQ
TNXP
Tonix Pharmaceuticals Holding CORP
10-K: Tonix Pharmaceuticals Outlines Stock Structure and Pipeline Progress in Annual Filing
Tonix Pharmaceuticals' annual filing details its stock structure, clinical pipeline, and commercialization efforts, highlighting the upcoming NDA submission for Tonmya.